301075 Tibet Duo Rui Pharmaceutical
- 19.61
- +0.14+0.72%
Tibet Duo Rui Pharmaceutical News
Dorui Pharmaceutical (301075.SZ): The repurchase was completed with a cumulative cost of 20.983,300 yuan to repurchase 1.044,500 shares
Glonghui, May 7, 丨 Dorui Pharmaceutical (301075.SZ) announced that as of April 30, 2024, the company had repurchased a total of 1.044,500 shares of the company's shares through a special stock repurchase securities account, accounting for 1.31% of the company's current total share capital. The highest transaction price was 21.10 yuan/share, the minimum transaction price was 18.21 yuan/share, and the total transaction amount was 20.9833 million yuan (excluding transaction fees). The company has completed this repurchase.
Dorui Pharmaceuticals (301075.SZ) announced first-quarter results, with a net loss of 2,5373 million yuan, an increase of 4.97% over the previous year
Dorui Pharmaceuticals (301075.SZ) released its report for the first quarter of 2024, with revenue of 784.574 million...
Dorui Pharmaceuticals (301075.SZ): 2023 net profit of 18.857,700 yuan, plans to distribute 10 to 1.25 yuan
On April 17, Ge Longhui Pharmaceutical (301075.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 334 million yuan, a year-on-year decrease of 16.64%; net profit attributable to shareholders of listed companies was 18.8507 million yuan, a year-on-year decrease of 8.05%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 5.258 million yuan, a year-on-year decrease of 34.96%; basic earnings per share of 0.24 yuan; it plans to distribute a cash dividend of 1.25 yuan (tax included) for every 10 shares to all shareholders.
Dorui Pharmaceutical (301075.SZ): A total cost of 19.178,900 yuan to buy back 1.19% of the shares
Glonghui, March 29丨Dorui Pharmaceutical (301075.SZ) announced that as of March 28, 2024, the company had repurchased 955,300 shares of the company's shares through a special stock repurchase securities account, accounting for 1.19% of the company's current total share capital. The highest transaction price was 21.10 yuan/share, the lowest transaction price was 18.21 yuan/share, and the total transaction amount was 19,178,878.41 yuan.
Dorui Pharmaceutical (301075.SZ): Proposed construction of pharmaceutical raw materials and intermediates projects
On March 20, Gelonghui Pharmaceutical (301075.SZ) announced that in order to enrich the production platform for pharmaceutical intermediates and APIs and further improve the company's industrial chain layout, Tibet Dorui Pharmaceutical Co., Ltd. plans to sign a “Contract for Investment in the Construction of Pharmaceutical Ingredients and Intermediates Projects” with the Yicheng Municipal People's Government. The project is located in the Xiangyang (Yicheng) Fine Chemical Industrial Park and covers an area of 128 acres. The details are as specified in the state-owned land use rights concession contract. The project aims to make full use of the location advantages of Yicheng Fine Chemical Park, rely on the existing foundation of the subsidiary Hubei Xinchengda Chemical Co., Ltd. to enrich pharmaceutical intermediates and
Express News | Dorui Pharmaceutical: Plans to sign a project investment agreement with the Yicheng Municipal People's Government
Dorui Pharmaceuticals (301075.SZ): Repurchase 100,000 shares for the first time on March 4
Gelonghui, March 5, 丨 Dorui Pharmaceutical (301075.SZ) announced that on March 4, 2024, the company repurchased 100,000 shares of the company's shares through a dedicated repurchase account, accounting for 0.13% of the company's current total share capital. The highest transaction price was 19.00 yuan/share, the lowest transaction price was 18.60 yuan/share, and the total transaction amount was 1,886,995.41 yuan (excluding transaction fees).
Express News | Dorui Pharmaceutical: Plans to buy back the company's shares for 20 million yuan to 30 million yuan
Express News | Dorui Pharmaceuticals: Transferring 49% of the shares held by Renault that have not been paid for to Jiangxi Colon and Hubei Medicina for $0.0,000
Dorui Pharmaceutical (301075.SZ) plans to hold Hongxi Medical to enter the field of chronic kidney disease management
Dorui Pharmaceutical (301075.SZ) announced that the company recently signed an “Investment Cooperation Agreement”, and the company received it for 200,000 yuan...
Dorui Pharmaceutical (301075.SZ): Plans to transfer 51% of Hongxi Medical's shares for $0.0,000 (unpaid)
Gelonghui, January 17丨Dorui Pharmaceutical (301075.SZ) announced that in order to further enrich the company's business layout and create new profit growth points, Tibet Dorui Pharmaceutical Co., Ltd. recently signed an “Investment Cooperation Agreement”. The company took over the shares of Hongxi Medical Technology (Tianjin) Co., Ltd. (“Hongxi Medical” for short, the “Target Company”) held by Li Zhanbing, Tian Bin, Zhang Hengrui, and Xiong Rongliang with a registered capital of 5.1 million yuan (unpaid). The company will invest 5.1 million yuan in Hongxi Medical to fulfill the obligation to pay the capital. After the equity transfer was completed, the company held Hongxi Healthcare
Jiaxing Qiuyu, a shareholder of Dorui Pharmaceuticals (301075.SZ), completed a cumulative reduction of 2% of shares
Dorui Pharmaceutical (301075.SZ) announced that the company's shareholder Jiaxing Qiuyu's holdings reduction plan has expired, and it has passed centralized bidding...
The controlling shareholder of Dorui Pharmaceutical (301075.SZ) lifted the pledge of 4.1 million shares
Dorui Pharmaceutical (301075.SZ) announced that the company's controlling shareholder Dongxizang Jiakang Times Technology Development Co., Ltd. (“West...
Jiaxing Qiuyu, a shareholder of Dorui Pharmaceutical (301075.SZ), reduced its shareholding ratio by a total of 1%
Duorui Pharmaceutical (301075.SZ) announced that the company's shareholder Jiaxing Qiuyu invests in partnership (limited partnership) (“Jia...
Dorui Pharmaceutical (301075.SZ): Tranexamic acid injection obtained drug registration certificate
Dorui Pharmaceutical (301075.SZ) announced that Hubei Duorui Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently received from the country...
Pharmaceutical stocks collectively adjusted in the direction of CRO and led the decline
Glonway, August 15 | Dorui Pharmaceutical fell nearly 10%, while Xintiandi, Jiuzhou Pharmaceutical, Medicinal Stone Technology, Haite Biotech, and Hongbo Pharmaceutical fell more than 5%.
Dorui Pharmaceutical (301075.SZ): Jiaxing Qiuyu has reduced its share holdings by a cumulative total of 1.00%
GLONGHUI, August 14丨Dorui Pharmaceutical (301075.SZ) announced that from August 9 to 11, 2023, Jiaxing Qiuyu Investment Partnership (Limited Partnership) (“Jiaxing Qiuyu”) reduced its holdings of the company's shares by 820 million shares through centralized bidding, a reduction ratio of 1.00%. Currently, not all of the holdings reduction plans have been implemented.
Dorui Pharmaceutical (301075.SZ): No raw materials for diet pills
GLONGHUI August 11丨Some investors asked Dorui Pharmaceuticals (301075.SZ), “I heard that the company has ingredients for diet pills, is that true?” Dorui Pharmaceutical replied that the company had no relevant APIs.
Dorui Pharmaceutical (301075.SZ) plans to acquire 55% of Xincheng's shares to improve the layout of the pharmaceutical industry chain
According to the Zhitong Finance App, Dorui Pharmaceutical (301075.SZ) announced that the company signed an “Investment Cooperation Agreement” with Shengxiang Chemical, Wuhan Jinshengxing Automatic Control Engineering Co., Ltd. (“Jin Shengxing”), and Xin Chengda, to transfer 30.5% and 7.625% of the shares of Xinchengda held by Shengxiang Chemical and Jin Shengxing respectively with its own capital or self-financing of RMB 30.00 million (including prepaid funds of RMB 20 million) Xin Chengda increased its capital. After the transaction is completed, the registered capital of the target company is 103 million yuan, and the company will
Dorui Pharmaceutical (301075.SZ): Classic recipes of traditional Chinese medicine are in the trial/pilot study stage
Gronway July 28丨Some investors asked Dorui Pharmaceuticals (301075.SZ), “What is your company doing in the field of traditional Chinese medicine? What products are already available?” Dorui Pharmaceutical replied that currently, the new class 1 traditional Chinese medicine being developed by the company is preparing for phase II clinical trials. Classic recipes of traditional Chinese medicines are in the trial/pilot study stage. For the relevant situation, please pay attention to the regular reports and related announcements.
Analysis
Price Target
No Data
